Factores clínicos preditivos de complicações na doença de Crohn.

Crohn's disease (CD) is a progressive disease that is subdivided in three phenotypes: inflammatory, stricturing, and penetrating. At diagnosis most CD patients have inflammatory disease. However, the natural history of CD evolves over time to structural digestive tract complications (strictures and fistulae) which are associated with hospitalisations and surgeries. Nowadays, there is evidence that early treatment with immunosuppressants and biologics can interrupt the development of inflammation- destruction/fibrosis through its potential to induce complete mucosal healing. The change in CD natural history, mediated by mucosal healing, is associated with a reduction in serious complications (hospitalisations and surgeries). Nevertheless, the clinical course of CD varies considerably between patients and there is still no definition for the timing of immunosuppressants and/or biologics use. This medication is associated to certain risks (lymphomas and opportunistic infections) and the difficulty to predict, on an individual basis, the progression to complications have triggered efforts to identify risk factors that allow at diagnosis to classify patients in high and low risk groups and to tailor therapy. This paper is an updated compilation of evidence of clinical risk factors predictive for CD complications.Crohn's disease (CD) is a progressive disease that is subdivided in three phenotypes: inflammatory, stricturing, and penetrating. At diagnosis most CD patients have inflammatory disease. However, the natural history of CD evolves over time to structural digestive tract complications (strictures and fistulae) which are associated with hospitalisations and surgeries. Nowadays, there is evidence that early treatment with immunosuppressants and biologics can interrupt the development of inflammation- destruction/fibrosis through its potential to induce complete mucosal healing. The change in CD natural history, mediated by mucosal healing, is associated with a reduction in serious complications (hospitalisations and surgeries). Nevertheless, the clinical course of CD varies considerably between patients and there is still no definition for the timing of immunosuppressants and/or biologics use. This medication is associated to certain risks (lymphomas and opportunistic infections) and the difficulty to predict, on an individual basis, the progression to complications have triggered efforts to identify risk factors that allow at diagnosis to classify patients in high and low risk groups and to tailor therapy. This paper is an updated compilation of evidence of clinical risk factors predictive for CD complications